Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced it entered into an exclusive agreement with a subsidiary of Santen Pharmaceutical, to co-commercialize an undisclosed ophthalmology therapeutic product currently under review by Health Canada for marketing approval in Canada.
As quoted in the press release:
“We are delighted to collaborate with Santen, a company with a rich history and focus in ophthalmology, as it seeks to bring innovative eye care therapies to patients in Canada affected by ophthalmic diseases. This agreement recognizes and builds upon the commitment of both companies to provide patients with high-quality and differentiated therapies, and will add to the commercial ophthalmology franchise we have been building at Aequus since the successful launch of Vistitan in 2016,” said Doug Janzen, Chairman and CEO of Aequus.
“We have a proven track record and well established relations with key Canadian stakeholders in ophthalmology,” said Ian Ball, Chief Commercial Officer at Aequus. “The addition of Santen’s ophthalmology product and experience to Aequus’ existing product offering will further strengthen our growing ophthalmology portfolio and demonstrates our commitment to grow in this important therapeutic area.”
“Santen is pleased to partner with Aequus and looks forward to leveraging our joint expertise and resources to make important treatment options available for patients in Canada,” said Akihiro Tsujimura, Executive Corporate Officer and Head of Santen North America. “Aequus is an ideal partner for a specialty ophthalmic company, given their well-established sales force and relationships with eye care specialists. This collaboration further reinforces Santen’s mission to bring ophthalmic therapies to patients around the world.”